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Abstract	  




Human	  platelets	  play	  a	  vital	  role	  in	  both	  hemostasis	  and	  thrombosis.	  Deficiencies	  in	  platelet	  number	  or	  function	  can	  cause	  excessive	  bleeding.	  Hyperactive	  platelets	  adhere	  to	  and	  aggregate	  on	  blood	  vessels	  and	  cause	  thrombotic	  diseases,	  such	  as	  heart	  attack	  or	  stroke,	  which	  are	  two	  leading	  causes	  of	  death	  in	  the	  U.S.	  according	  to	  World	  Health	  Organization	  (WHO	  online).	  Human	  platelets	  respond	  to	  multiple	  agonists,	  including	  collagen,	  thrombin	  and	  ADP	  (Shattil,	  S.	  J.,	  2010).	  The	  activation	  of	  agonist	  receptors	  causes	  downstream	  intracellular	  cascades	  that	  activate	  an	  important	  integrin	  αΙΙbβ3	  on	  platelet	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membranes.	  Integrin	  αΙΙbβ3	  activation	  changes	  its	  affinity	  for	  extracellular	  ligands,	  such	  as	  fibrinogen	  and	  fibronectin,	  therefore	  causing	  platelet	  aggregation	  and	  thrombosis.	  Most	  anti-­‐platelet	  therapies	  target	  agonist	  receptors,	  integrin	  αΙΙbβ3	  or	  intracellular	  cyclooxygenase	  (COX1)	  (Phillips,	  D.	  R.	  et	  al.	  2005;	  Morrow,	  D.	  A.	  et	  al.	  2013;	  Tricoci,	  P.	  et	  al.	  2012;	  	  Wallentin,	  L.	  et	  al.	  2009).	  However,	  they	  all	  have	  side	  effects,	  such	  as	  excessive	  bleeding.	  Therefore,	  new	  drug	  targets	  that	  have	  the	  potential	  to	  decrease	  bleeding	  effects	  are	  needed	  for	  advancing	  antithrombotic	  treatment.	  	  
	  
We	  recently	  discovered	  a	  novel	  enzyme	  in	  human	  platelet	  named	  arylacetamide	  deacetylase-­‐like	  1	  (AADACL1),	  also	  known	  as	  KIAA	  1363	  or	  NCEH1	  that	  regulates	  ether	  lipids	  metabolism	  and	  platelet	  activation	  (Holly,	  S.P.,	  2013).	  	  AADACL1	  has	  one	  known	  lipid	  substrate,	  1-­‐O-­‐hexadecyl-­‐2-­‐O-­‐acetyl-­‐sn-­‐glycerol	  (HAG	  or	  2-­‐acetyl	  MAGE),	  but	  two	  others	  have	  been	  implicated	  by	  our	  group	  and	  others	  (Holly	  et	  al.	  2013,	  Chiang	  2006).	  The	  lipid	  substrate	  2-­‐acetyl	  MAGE	  is	  deacetylated	  by	  AADACL1	  to	  form	  MAGE	  (Figure	  1).	  	  Inhibition	  of	  AADACL1	  activity	  with	  a	  small	  molecule	  inhibitor	  JW480	  blocks	  integrin	  αΙΙbβ3	  activation	  and	  platelet	  aggregation	  in	  response	  to	  multiple	  agonists,	  especially	  collagen	  (Holly,	  S.P.,	  2013).	  Most	  interestingly,	  2-­‐acetyl	  MAGE	  has	  the	  same	  effects	  on	  platelets	  as	  if	  AADACL1	  is	  inhibited	  by	  JW480.	  At	  a	  molecular	  level,	  we	  also	  showed	  that	  AADACL1	  regulates	  RAP1,	  a	  major	  monomeric	  G-­‐protein	  that	  regulates	  platelet	  and	  integrin	  activation,	  and	  protein	  kinase	  C	  (PKC),	  which	  catalyzes	  ADP	  secretion	  in	  response	  to	  collagen	  and	  other	  agonists	  (Figure	  2).	  However,	  the	  exact	  molecular	  mechanism	  of	  AADACL1	  regulation	  of	  the	  collagen	  activation	  pathway	  is	  still	  elusive.	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The	  inhibition	  of	  AADACL1	  under	  in	  vitro	  flow	  conditions	  mimics	  blockade	  of	  integrin	  αΙΙbβ3	  by	  eptifibatide,	  an	  FDA	  approved	  anti-­‐thrombotic	  drug	  (Scarborough	  et	  al,	  1993).	  In	  addition	  to	  this,	  we	  think	  that	  AADACL1	  blockage	  would	  not	  lead	  to	  excessive	  bleeding	  problems	  since	  AADACL1	  appears	  to	  impact	  collagen	  signaling	  more	  so	  than	  thrombin	  signaling,	  making	  it	  a	  potential	  drug	  target	  with	  minimal	  side	  effects.	  In	  order	  to	  explore	  the	  full	  potential	  of	  AADACL1	  in	  platelet	  treatment,	  we	  are	  trying	  to	  elucidate	  its	  precise	  molecular	  mechanism	  in	  regulating	  platelet	  activation.	  	  
	  
Based	  on	  our	  previous	  findings	  and	  the	  PKC	  literature,	  we	  hypothesize	  that	  when	  AADACL1	  is	  inhibited	  in	  platelets,	  its	  lipid	  substrate,	  2-­‐acetyl	  MAGE,	  might	  accumulate,	  and	  bind	  to	  PKC	  lipid	  binding	  domains,	  which	  may	  result	  in	  decreased	  PKC	  activity	  and	  impaired	  ADP	  secretion.	  We	  also	  hypothesize	  that	  2-­‐acetyl	  MAGE	  might	  bind	  to	  the	  nucleotide	  exchange	  factor	  of	  RAP1,	  CALDAG	  GEF1	  (CDG1)	  and	  inhibit	  its	  activity.	  We	  have	  begun	  validating	  this	  hypothesis	  by	  testing	  the	  physical	  binding	  of	  2-­‐acetyl	  MAGE	  to	  a	  PKC	  and	  CDG1	  lipid	  binding	  domain,	  looking	  at	  2-­‐acetyl	  MAGE	  effects	  on	  protein	  kinase	  activity	  in	  vitro	  and	  checking	  PKC	  activation	  status	  in	  JW480-­‐treated	  platelets.	  	  
	  
A.	   B.	  
Figure	  1.	  AADACL1	  in	  human	  platelets	  	  A)	  AADACL1	  regulation	  of	  lipid	  metabolism	  B)	  Collagen	  activation	  pathway	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Results	  and	  Discussion	  




Figure	  2.	  PKCδ	  C1b	  binds	  2-­‐acetyl	  MAGE	  A)	  Intrinsic	  tryptophan	  fluorescence	  of	  PKCδ	  C1b	  B-­‐C)	  Binding	  affinity	  of	  PMA	  and	  2-­‐acetyl	  MAGE	  to	  PKCδ	  C1b	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at	  280	  nm	  and	  the	  emission	  signal	  was	  observed	  at	  350	  nm.	  The	  200nM	  peptide	  generated	  5-­‐fold	  higher	  fluorescence	  signal	  than	  buffer	  and	  this	  concentration	  of	  peptide	  was	  used	  for	  the	  following	  binding	  tests	  (Figure	  2A).	  The	  positive	  control,	  PMA,	  bound	  to	  PKCδ	  C1b	  with	  a	  Kd	  of	  61.2	  ±	  8	  nM	  (Figure	  2B).	  Similar	  to	  PMA,	  monomers	  of	  2-­‐acetyl	  MAGE	  bound	  to	  the	  PKCδ	  C1b	  peptide	  with	  a	  Kd	  value	  of	  105	  ±	  17	  nM	  (Figure	  2C).	  PKCδ	  C1b	  did	  not	  significantly	  bind	  phosphatidylcholine	  (PC)	  monomers	  (data	  not	  shown).	  	  In	  order	  to	  mimic	  the	  physiological	  environment	  of	  lipids	  in	  cells,	  we	  incorporated	  2-­‐acetyl	  MAGE	  or	  a	  positive	  control	  lipid,	  DAG,	  together	  with	  common	  membrane	  phospholipids	  PC	  and	  phosphatidylserine	  (PS)	  into	  small	  unilamellar	  vesicles	  (SUV).	  	  SUVs	  without	  2-­‐acetyl	  MAGE	  or	  DAG	  showed	  minimal	  binding	  to	  the	  PKCδ	  C1b	  peptide	  (Table.1).	  The	  positive	  control	  SUVs	  containing	  DAG	  bound	  to	  PKCδ	  C1b	  peptide	  with	  a	  Kd	  of	  5.0	  ±	  0	  nM.	  Similarly,	  SUVs	  containing	  2-­‐acetyl	  MAGE	  bound	  to	  PKCδ	  C1b	  with	  a	  Kd	  of	  21	  ±	  3	  nM,	  which	  was	  five-­‐fold	  higher	  than	  2-­‐acetyle	  MAGE	  monomer	  binding.	  Also,	  we	  tested	  the	  MAGE	  SUV	  binding	  to	  PKCδ	  C1b	  and	  found	  a	  Kd	  of	  8.5	  ±	  0.5	  nM.	  Both	  monomer	  binding	  and	  SUV	  binding	  results	  demonstrate	  that	  2-­‐acetyl	  MAGE	  bound	  to	  the	  PKCδ	  C1b	  peptide	  with	  high	  affinity.	  	  	  	  




	   Control	   DAG	   2-­‐acetyl-­‐MAGE	   MAGE	  Kd	  (nM)	   278	  ±	  7.5	  	   	  5.0	  ±	  0	  	   22	  ±	  1.5	  	   8.5	  ±	  0.5	  n	   2	   2	   2	   2	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2-­‐acetyl	  MAGE	  does	  not	  bind	  to	  lipid	  binding	  domain	  of	  CALDAG	  GEF1	  	  We	  knew	  from	  previous	  experiments	  that	  AADACL1	  regulated	  RAP1	  activity	  and	  we	  think	  that	  this	  regulation	  was	  caused	  by	  the	  binding	  event	  between	  2-­‐acetyl	  MAGE	  to	  the	  CDG1	  lipid	  binding	  domain	  which	  further	  inhibited	  RAP1	  activity.	  	  The	  CDG1	  lipid	  binding	  domain	  peptide	  did	  not	  have	  a	  tryptophan	  residue	  in	  the	  middle	  so	  that	  its	  intrinsic	  fluorescent	  signal	  was	  low	  (data	  not	  shown).	  Therefore,	  we	  tested	  binding	  using	  co-­‐sedimentation	  assay.	  	  The	  CDG1	  lipid	  binding	  domain	  peptide	  was	  incubated	  with	  large	  unilamellar	  vesicles	  (LUV),	  which	  would	  be	  pulled	  down	  in	  pellet	  form	  when	  centrifuged.	  The	  portion	  of	  peptide	  that	  bound	  to	  LUVs	  would	  be	  pulled	  down	  in	  pellet	  and	  that	  did	  not	  	  
	  
	  bind	  would	  stay	  in	  supernatant	  form.	  	  Our	  data	  (Figure	  3-­‐A)	  suggested	  that	  most	  of	  the	  CDG1	  peptide	  appeared	  in	  supernatant	  form	  after	  incubation	  with	  2-­‐acetyl	  MAGE	  and	  centrifugation,	  which	  was	  similar	  to	  the	  control	  group.	  The	  quantitation	  results	  (Figure	  3-­‐B)	  suggested	  that	  the	  CDG1	  peptide	  bound	  to	  2-­‐acetyl	  MAGE	  vesicles	  with	  only	  8%	  binding	  affinity,	  almost	  the	  same	  as	  its	  affinity	  to	  the	  control	  vesicle	  which	  did	  not	  have	  2-­‐acetyl	  MAGE	  or	  DAG	  incorporated.	  From	  here,	  we	  were	  confident	  that	  CDG1	  lipid	  binding	  domain	  peptide	  did	  not	  bind	  to	  2-­‐acetyl	  
Peptide	  ~6kD	   





control	  	   PKC+DAG	   CDG1+2-­‐acetyl	  MAGE	  
A.	   B.	  
Figure	  3.	  2-­‐acetyl	  MAGE	  does	  not	  bind	  to	  CDG1	  	  
A) Most of the CDG1 peptide appeared in supernatant form while interacting with 2-acetyl MAGE  
B) Percent binding of peptide to lipids. N=2 
C)  
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MAGE,	  and	  this	  ruled	  out	  the	  possibility	  that	  2-­‐acetyl	  MAGE	  regulates	  RAP1	  activation	  through	  interacting	  with	  its	  nucleotide	  exchange	  factor,	  CDG1.	  Therefore,	  we	  thought	  that	  2-­‐acetyl	  MAGE	  is	  regulating	  platelets	  activation	  through	  PKC	  activity	  and	  we	  focused	  on	  PKCs	  in	  our	  following	  experiments.	  	  
2-­‐acetyl	  MAGE	  decreases	  PKC	  kinase	  activity	  The	  results	  of	  the	  binding	  experiment	  were	  consistent	  with	  our	  hypothesis	  that	  2-­‐acetyl	  MAGE	  physically	  interacted	  with	  PKC	  lipid	  binding	  domain,	  and	  the	  next	  step	  was	  to	  test	  whether	  the	  binding	  events	  had	  any	  effect	  on	  PKC	  kinase	  activity	  in	  vitro.	  We	  used	  a	  commercially	  available	  fluorescently	  labeled	  PKC-­‐specific	  substrate.	  The	  percent	  phosphorylation	  of	  this	  peptide	  was	  a	  direct	  indication	  of	  PKC	  kinase	  activity.	  We	  incubated	  the	  substrate	  with	  purified	  full-­‐length	  PKCδ	  enzyme	  with	  PMA	  and/or	  2-­‐acetyl	  MAGE	  monomers	  and	  calculated	  percent	  phosphorylation	  of	  the	  substrate.	  In	  the	  absence	  of	  PMA,	  2-­‐acetyl	  MAGE	  itself	  did	  not	  activate	  PKCδ	  enzyme	  (data	  not	  shown).	  This	  is	  important	  because	  even	  though	  2-­‐acetyl	  MAGE	  binds	  PKC,	  this	  lipid	  is	  not	  an	  activator	  like	  DAG.	  In	  the	  presence	  of	  PMA,	  PKCδ	  enzyme	  was	  activated.	  When	  increasing	  concentrations	  of	  2-­‐acetyl	  MAGE	  monomers	  were	  added	  to	  the	  reaction	  containing	  PMA,	  we	  saw	  decreased	  PKCδ	  activity	  up	  to	  35%	  (Figure	  4).	  Due	  to	  the	  low	  number	  of	  experiments	  and	  the	  variability	  in	  the	  assay,	  only	  the	  2	  µM	  concentration	  of	  2-­‐acetyl	  MAGE	  
Figure	  4.	  2-­‐Acetyl	  MAGE	  effect	  on	  PMA	  induced	  PKC	  	   	  	  
activity.	  Should	  say	  something	  about	  how	  the	  data	  were	  
normalized	  (N=3)	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showed	  statistically	  significant	  inhibition	  compared	  to	  controls.	  This	  result	  was	  consistent	  with	  our	  hypothesis	  that	  the	  binding	  of	  2-­‐acetyl	  MAGE	  to	  PKCδ	  decreases	  kinase	  activity.	  
	  
AADACL1	  regulates	  PKC	  activation	  in	  human	  platelets	  In	  classical	  (α,	  β)	  and	  novel	  forms	  (δ,	  ε,	  θ)	  of	  PKCs,	  there	  are	  three	  phosphorylation	  events	  important	  for	  enzyme	  activation.	  Firstly,	  PKC	  gets	  phosphorylated	  by	  phosphatidylinositide-­‐dependent	  kinase-­‐1	  (PDK-­‐1)	  at	  the	  threonine	  T500	  position.	  This	  is	  followed	  by	  two	  auto-­‐phosphorylation	  events	  at	  threonine	  641	  and	  serine	  660	  (Kazanietz,	  M.G.	  2011).	  Once	  these	  three	  sites	  are	  phosphorylated,	  PKC	  enzyme	  is	  activated	  and	  is	  ready	  to	  respond	  to	  lipid	  second	  messengers,	  such	  as	  DAG.	  We	  tested	  the	  phosphorylation	  status	  of	  PKCδ	  T505	  in	  human	  platelets	  lysate.	  This	  phosphorylation	  event	  is	  the	  first	  step	  of	  PKC	  activation	  and	  we	  used	  it	  as	  an	  indicator	  of	  cellular	  PKC	  activity.	  We	  pretreated	  human	  platelets	  with	  and	  without	  JW480,	  stimulated	  platelets	  with	  an	  agonist,	  collagen,	  and	  checked	  PKCδ	  T505	  phosphorylation	  status	  using	  a	  site-­‐specific	  antibody.	  PKCδ	  T505	  showed	  a	  low	  level	  of	  phosphorylation	  without	  agonist	  (Figure	  5A).	  With	  agonist,	  PKCδ	  T505	  phosphorylation	  decreased	  with	  increasing	  amounts	  of	  JW480,	  the	  AADACL1	  
Figure	  5.	  AADACL1	  regulates	  PKC	  phosphorylation	  in	  platelets	  	  A)	  PKCδ	  T505	  phosphorylation	  decreased	  with	  increasing	  amount	  of	  JW480;	  pleckstrin	  level	  as	  loading	  control	  B)	  Quantitation	  of	  the	  blots;	  PKC	  phosphorylation	  was	  normalized	  to	  pleckstrin	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inhibitor,	  up	  to	  45%.	  The	  data	  was	  normalized	  to	  a	  loading	  control	  protein,	  pleckstrin	  (Figure	  5B).	  From	  this	  experiment,	  we	  concluded	  that	  AADACL1	  was	  regulating	  platelet	  activity	  through	  modulating	  PKC	  function.	  In	  addition,	  our	  preliminary	  data	  suggested	  10uM	  2-­‐acetyl	  MAGE	  almost	  completely	  inhibited	  PKCδ	  T505	  phosphorylation	  (Data	  not	  shown).	  	  	  	  
Discussion	  	  AADACL1	  has	  been	  shown	  to	  regulate	  human	  platelet	  activity	  through	  the	  collagen	  activation	  pathway	  (Holly,	  S.P.,	  2013).	  It	  is	  less	  effective	  and	  variable	  in	  its	  ability	  to	  regulate	  aggregation	  stimulated	  by	  thrombin.	  	  Therefore,	  we	  think	  this	  enzyme	  is	  a	  desirable	  drug	  target	  for	  thrombotic	  diseases	  since	  it	  has	  the	  potential	  to	  impair	  thrombosis	  while	  preserving	  hemostasis.	  My	  work	  was	  focused	  on	  elucidating	  the	  molecular	  mechanism	  of	  AADACL1	  in	  regulating	  platelet	  activation	  pathways.	  Based	  on	  our	  previous	  experiments	  and	  literature,	  we	  hypothesized	  that	  the	  lipid	  substrate	  of	  AADACL1,	  2-­‐acetyl	  MAGE	  acts	  as	  an	  inhibitor	  of	  PKC	  family	  kinases	  and	  therefore	  decreased	  platelet	  activation.	  The	  results	  confirmed	  that	  2-­‐acetyl	  MAGE	  bound	  tightly	  to	  a	  PKC	  lipid	  binding	  domain,	  inhibited	  PKC	  kinase	  activity	  and	  that	  AADACL1	  affected	  PKC	  activation	  status	  in	  agonist-­‐stimulated	  platelets.	  	  	  The	  intrinsic	  fluorescence	  data	  showed	  that	  2-­‐acetyl	  MAGE	  bound	  to	  the	  PKCδ	  C1b	  domain	  with	  high	  affinity,	  almost	  comparable	  to	  the	  lipid	  activator,	  DAG,	  suggesting	  its	  capability	  to	  compete	  for	  binding	  sites	  on	  PKC	  lipid	  binding	  domain	  with	  DAG.	  By	  displacing	  the	  lipid	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activator	  from	  PKC	  C1	  domain,	  2-­‐acetyl	  MAGE	  could	  inhibit	  PKC	  enzyme	  activity.	  Most	  interestingly,	  we	  found	  that	  the	  deacetylated	  product	  of	  AADACL1,	  MAGE	  also	  binds	  to	  PKCδ	  C1b	  with	  an	  even	  higher	  binding	  affinity	  than	  2-­‐acetyl	  MAGE.	  This	  might	  suggest	  that	  MAGE,	  along	  with	  2-­‐acetyl	  MAGE	  interacts	  with	  PKC	  isoforms	  and	  regulates	  PKC	  activity.	  According	  to	  our	  previous	  findings,	  2-­‐acetyl	  MAGE	  and	  JW480	  blocked	  platelet	  aggregation,	  but	  MAGE	  did	  not	  rescue	  this	  effect	  (Holly,	  S.P.,	  2013).	  Therefore,	  we	  think	  that	  the	  binding	  events	  of	  MAGE	  to	  PKCδ	  would	  not	  affect	  PKC	  activity	  in	  cells.	  Further	  investigation	  is	  needed	  to	  confirm	  this	  hypothesis.	  Besides,	  2-­‐acetyl	  MAGE	  in	  vesicle	  form	  bound	  to	  PKCδ	  C1b	  with	  5-­‐fold	  higher	  binding	  affinity	  than	  in	  its	  monomer	  form.	  This	  suggested	  that	  having	  lipids	  in	  a	  more	  physiological	  environment	  was	  very	  important	  in	  testing	  interactions	  with	  PKC.	  We	  also	  confirmed	  that	  2-­‐acetyl	  MAGE	  did	  not	  bind	  to	  the	  nucleotide	  exchange	  factor	  of	  RAP1,	  CDG1,	  suggesting	  that	  2-­‐acetyl	  MAGE	  regulated	  platelet	  activation	  through	  modulating	  PKC	  activity.	  	  	  	  	  Although	  the	  results	  of	  our	  protein	  kinase	  assay	  showed	  a	  decreased	  PMA-­‐stimulated	  PKC	  activity	  in	  the	  presence	  of	  2-­‐acetyl	  MAGE	  monomers,	  the	  results	  were	  not	  dose	  dependent.	  Ideally,	  we	  expected	  to	  see	  PKC	  enzyme	  activity	  decreased	  with	  increasing	  dose	  of	  2-­‐acetyl	  MAGE.	  However,	  the	  data	  showed	  that	  2-­‐acetyl	  MAGE	  at	  2	  µM	  concentration	  most	  strongly	  inhibited	  PKC	  kinase	  activity.	  Even	  though	  we	  have	  estimated	  the	  critical	  micelle	  concentration	  of	  2-­‐acetyl	  MAGE	  to	  be	  10	  µM,	  it	  is	  possible	  that	  2-­‐acetyl	  MAGE	  monomers	  have	  maximal	  activity	  at	  2	  µM.	  Lipids	  at	  higher	  concentration	  may	  still	  have	  aggregated	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under	  our	  experimental	  conditions,	  which	  would	  make	  them	  no	  longer	  capable	  of	  inhibiting	  PKC	  activity.	  	  	  PKCδ	  phosphorylation	  in	  human	  platelets	  pretreated	  with	  JW480,	  the	  AADACL1	  inhibitor,	  decreased	  dose	  dependently	  with	  increasing	  amounts	  of	  JW480,	  suggesting	  that	  AADACL1	  inhibition	  blocked	  PKC	  activation.	  Since	  PKCδ	  T505	  phosphorylation	  is	  the	  first	  step	  in	  PKC	  activation,	  it	  is	  a	  good	  indication	  of	  PKC	  activation	  status.	  However,	  it	  is	  not	  sufficient	  to	  suggest	  full	  kinase	  activity.	  Further	  experiments	  are	  needed	  to	  further	  measure	  PKC	  kinase	  activity	  in	  the	  cell,	  such	  as	  testing	  phosphorylation	  status	  of	  the	  other	  two	  critical	  auto-­‐phosphorylation	  sites	  on	  the	  C-­‐terminus	  of	  PKC	  and/or	  PKC-­‐specific	  substrates	  in	  platelets.	  Although	  this	  experiment	  was	  not	  an	  observation	  of	  the	  effect	  of	  2-­‐acetyl	  MAGE	  on	  human	  platelets,	  it	  was	  direct	  proof	  that	  AADACL1	  decreases	  platelet	  activation	  through	  regulating	  PKC	  activity.	  And	  our	  preliminary	  data	  suggested	  PKCδ	  T505	  phosphorylation	  status	  was	  inhibited	  by	  high	  concentration	  of	  2-­‐acetyl	  MAGE.	  	  	  	  Our	  data	  from	  these	  three	  experiments	  support	  our	  hypothesis.	  AADACL1	  regulates	  collagen	  stimulated	  platelet	  aggregation	  through	  PKC	  signaling	  pathways	  and	  its	  lipid	  substrate,	  2-­‐acetyl	  MAGE	  modulates	  PKC	  function.	  Further	  experiments	  need	  to	  be	  done	  to	  confirm	  the	  effects	  of	  2-­‐acetyl	  MAGE	  on	  other	  PKC	  isoforms.	  In	  addition,	  the	  effects	  of	  MAGE	  on	  PKC	  activity	  need	  to	  be	  verified.	  In	  order	  to	  get	  a	  more	  accurate	  indication	  of	  PKC	  activation	  status	  in	  the	  cell,	  we	  are	  planning	  on	  using	  similar	  methods	  in	  a	  platelet	  precursor	  cell	  line	  (CMK11-­‐15),	  testing	  the	  phosphorylation	  status	  of	  PKC	  isoforms	  to	  determine	  their	  kinase	  in	  cells.	  The	  advantage	  of	  using	  this	  cell	  line	  is	  that	  we	  can	  reduce	  
	   13	  
AADACL1	  protein	  levels	  via	  RNA	  interference	  and/or	  introduce	  PKC	  isoforms	  of	  interest	  via	  gene	  expression.	  	  
	  
Experimental	  Procedures	  	  
Intrinsic	  Fluorescence	  The	  tryptophan	  residue	  is	  intrinsically	  fluorescent;	  the	  excitation	  wavelength	  is	  at	  280	  nm	  and	  emission	  wavelength	  is	  at	  350	  nm.	  Solution	  of	  the	  PKCδ	  C1b	  domain	  peptide	  was	  made	  in	  binding	  buffer	  (20mM	  HEPES	  pH	  7.5,	  100mM	  NaCl,	  0.5mM	  ZnSO4).	  2-­‐acetyl	  MAGE	  in	  acetyl	  nitrile	  stock	  was	  dried	  down	  under	  nitrogen	  flow	  and	  resuspended	  in	  ethanol.	  Phorbol	  12-­‐myristate,	  13-­‐acetate	  (PMA)	  was	  used	  as	  positive	  control	  ligand	  for	  binding	  to	  the	  C1b	  domain.	  In	  a	  quartz	  cuvette,	  lipid	  monomers	  at	  the	  indicated	  concentrations	  were	  added	  to	  1	  mL	  of	  C1b	  domain	  peptide	  solution	  (200nM),	  and	  fluorescence	  signal	  was	  detected.	  All	  the	  data	  were	  obtained	  through	  a	  SPEX	  Fluorolog.	  SigmaPlot	  was	  used	  for	  hyperbolic	  decay	  curve	  fitting	  to	  generate	  dissociation	  constants.	  	  	  
SUV	  preparation	  Small	  unilamellar	  vesicles	  (SUV)	  containing	  2-­‐acetyl	  MAGE	  or	  DAG	  with	  radii	  of	  20	  nm	  were	  made	  to	  mimic	  the	  physiological	  environment	  of	  lipids.	  DAG	  or	  2-­‐acetyl	  MAGE	  (20	  mol%).	  dioleoyl	  phosphatidylcholine	  (DOPC,	  75	  mol%)	  and	  dioleoyl	  phosphatidylserine	  (DOPS,	  5	  mol%)	  were	  mixed	  in	  chloroform,	  dried	  down	  under	  nitrogen	  flow	  and	  dissolved	  in	  cyclohexane	  (1	  mL)	  with	  one	  drop	  of	  methanol.	  The	  sample	  was	  frozen	  in	  dry	  ice	  for	  0.5h	  and	  lyophilized	  overnight.	  The	  lipids	  were	  resuspended	  in	  binding	  buffer	  (200mM	  HEPES	  pH	  7.5,	  100mM	  NaCl)	  and	  sonicated	  (30s	  pulse,	  25s	  rest	  for	  7min)	  until	  clear.	  The	  vesicles	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(0.5mM	  total	  lipids)	  were	  spun	  at	  70,000	  rpm	  for	  25	  min	  at	  4	  °C,	  and	  the	  supernatant	  containing	  vesicles	  was	  collected.	  The	  vesicles	  was	  stored	  at	  4	  °C,	  out	  of	  light,	  for	  use	  in	  the	  binding	  experiment.	  The	  intrinsic	  fluorescence	  binding	  experiment	  of	  SUV	  to	  PKCδ	  C1b	  peptide	  was	  similar	  as	  described	  earlier.	  	  	  
Co-­‐sedimentation	  Assay	  CALDAG	  GEF1	  C1	  domain	  peptide	  was	  dissolved	  in	  binding	  buffer.	  Large	  unilamellar	  vesicle	  (LUV)	  with	  radius	  of	  100	  nm	  was	  made	  in	  binding	  buffer.	  The	  LUV	  preparation	  was	  similar	  to	  SUV	  preparation,	  instead	  of	  sonication,	  the	  lipids	  were	  extruded	  to	  form	  larger	  vesicles.	  The	  peptide	  (20uM)	  and	  LUVs	  (3mM	  total	  lipids)	  were	  incubated	  at	  37°C	  for	  1h	  and	  centrifuged	  at	  70,000	  rpm	  for	  30	  min	  at	  4	  °C	  to	  separate	  the	  supernatant	  and	  pellet.	  The	  pellet	  was	  resuspended	  in	  buffer.	  Lipid	  extraction	  (Wessel,	  D.	  and	  Flugge,	  U.I.,	  1983)	  was	  performed	  to	  recover	  the	  protein	  in	  the	  sample.	  Proteins	  were	  run	  on	  a	  polyacrylamide	  gel	  and	  were	  stained	  by	  SYPRO	  Ruby	  Protein	  Stain.	  Proteins	  that	  bound	  to	  lipid	  vesicles	  would	  appear	  in	  the	  pellet	  fraction	  and	  those	  did	  not	  bind	  would	  appear	  in	  the	  supernatant.	  PKCδ	  C1b	  domain	  with	  DAG	  was	  used	  as	  positive	  control	  of	  binding	  and	  CDG1	  C1	  with	  DAG	  was	  used	  as	  negative	  control.	  	  	  	  
Protein	  Kinase	  Assay	  Experimental	  procedure	  closely	  followed	  PepTag®	  Assay	  for	  Non-­‐Radioactive	  Detection	  of	  Protein	  Kinase	  C	  (see	  references).	  Lipids	  were	  resuspended	  in	  ethanol	  as	  described	  above.	  PMA	  (16	  µM)	  was	  used	  as	  positive	  control	  and	  2-­‐acetyl	  MAGE	  at	  indicated	  concentrations	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was	  added	  to	  PMA	  to	  test	  competition.	  Full	  length	  PKCδ	  purified	  from	  insect	  cells	  contained	  post-­‐translational	  modifications	  and	  was	  obtained	  from	  Promega.	  	  
	  
Western	  Blot	  Human	  platelets	  were	  purified	  and	  adjusted	  to	  3×108	  platelets/mL	  in	  HEPES-­‐Tyrode’s	  buffer	  in	  the	  absence	  of	  calcium	  as	  described	  (Holly	  et	  al.).	  Platelets	  were	  treated	  with	  indicated	  concentrations	  of	  JW480	  for	  0.5h	  and	  mixed	  with	  375	  ng/mL	  collagen.	  Platelets	  were	  lysed	  in	  2×buffer	  (40	  mM	  HEPES	  pH	  7.4,	  300	  mM	  NaCl,	  20	  mM	  CHAPS,	  10	  mM	  MgCl2,	  10%	  glycerol,	  2	  mM	  Na3VO4,	  2	  mM	  NaF,	  2	  mM	  β-­‐glycerophosphate,	  1	  mM	  NaPPi	  and	  protease	  inhibitors).	  PKCδ	  activation	  status	  was	  examined	  in	  lysates	  using	  anti-­‐phosphothreonine	  505	  substrate	  antibody	  (#9374P,	  Cell	  Signaling).	  These	  blots	  were	  stripped	  and	  reblotted	  with	  polyclonal	  anti-­‐pleckstrin	  antibody	  (clone	  25,	  BD	  Biosciences)	  to	  verify	  protein	  loading.	  	  	  	  	  	  	  	  	  	  	  	  
	   16	  
References	  	  
1. World Health Organization. The top 10 causes of death. 
http://www.who.int/mediacentre/factsheets/fs310/en (accessed Mar 21, 2015) 
2. Shattil, S. J. et al. Nat. Rev. Mol. Cell. Biol. 2010. 11(4), 288-300 
3. Holly, S.P. et al. Chem Biol. 2013. 20(9), 1125–1134 
4. Phillips, D. R. et al. J.Thromb.Haemost. 2005, 3, 1577-1589  
5. Morrow, D. A. et al. Stroke 2013, 44, 691-698  
6. Tricoci, P. et al. N.Engl.J.Med. 2012, 366, 20-33  
7. Wallentin, L. et al. The New England journal of medicine 2009, 361, 1045-1057 
8. Chiang, K. P. et al. Chem.Biol. 2006, 13, 1041-1050  
9. Scarborough, R. M. et al. J.Biol.Chem. 1993, 268, 1066-1073  
10. Leonard, T. A. et al. Cell 2011, 144, 55-66, doi:10.1016/j.cell.2010.12.013 
11. PepTag® Assay for Non-Radioactive Detection of Protein Kinase C 
	  
	  
